Teleflex (NYSE:TFX) Receives "Sell (D+)" Rating from Weiss Ratings

Key Points

• Teleflex's stock has been restated with a "sell (D+)" rating by Weiss Ratings, reflecting a cautious outlook among analysts.
• The company reported earnings per share of $3.73 for the last quarter, exceeding expectations, with revenue rising by 4.2% year-over-year.
• Insider trading activity includes purchases by directors, with one director increasing their stake by 67.36%, indicating confidence in the company's future.

Teleflex (NYSE:TFX - Get Free Report)'s stock had its "sell (d+)" rating restated by equities research analysts at Weiss Ratings in a research report issued to clients and investors on Friday,Weiss Ratings reports.

Several other equities analysts have also recently weighed in on TFX. Wall Street Zen cut Teleflex from a "strong-buy" rating to a "buy" rating in a research report on Monday, September 15th. Zacks Research cut Teleflex from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 30th. Royal Bank Of Canada lifted their price target on Teleflex from $130.00 to $135.00 and gave the company a "sector perform" rating in a research report on Friday, August 1st. Wells Fargo & Company reduced their price target on Teleflex from $137.00 to $131.00 and set an "equal weight" rating for the company in a research report on Friday, August 1st. Finally, Mizuho lifted their price target on Teleflex from $130.00 to $135.00 and gave the company a "neutral" rating in a research report on Friday, August 1st. One analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Reduce" and an average target price of $141.57.

Teleflex Price Performance

Shares of NYSE TFX opened at $132.12 on Friday. The stock has a market cap of $5.84 billion, a PE ratio of 31.09, a price-to-earnings-growth ratio of 1.85 and a beta of 1.05. Teleflex has a fifty-two week low of $108.90 and a fifty-two week high of $239.13. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.44 and a current ratio of 2.41. The stock has a fifty day moving average of $126.28 and a 200-day moving average of $123.68.

Teleflex (NYSE:TFX - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.36 by $0.37. The company had revenue of $780.90 million during the quarter, compared to analysts' expectations of $771.53 million. Teleflex had a return on equity of 15.08% and a net margin of 6.31%.The firm's quarterly revenue was up 4.2% compared to the same quarter last year. During the same period in the previous year, the business earned $3.42 earnings per share. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. Equities research analysts anticipate that Teleflex will post 13.98 earnings per share for the current year.

Insider Buying and Selling at Teleflex

In other news, Director Andrew A. Krakauer purchased 1,000 shares of the company's stock in a transaction on Tuesday, August 5th. The stock was purchased at an average price of $115.25 per share, with a total value of $115,250.00. Following the completion of the purchase, the director directly owned 7,192 shares in the company, valued at approximately $828,878. This trade represents a 16.15% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jaewon Ryu purchased 1,500 shares of the company's stock in a transaction on Tuesday, August 5th. The shares were purchased at an average cost of $115.00 per share, with a total value of $172,500.00. Following the purchase, the director owned 3,727 shares of the company's stock, valued at approximately $428,605. The trade was a 67.36% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 5,500 shares of company stock valued at $633,590 over the last 90 days. Insiders own 1.40% of the company's stock.

Institutional Investors Weigh In On Teleflex

Hedge funds have recently added to or reduced their stakes in the company. Banque Cantonale Vaudoise bought a new stake in Teleflex during the first quarter worth about $27,000. Costello Asset Management INC bought a new stake in Teleflex during the first quarter worth about $28,000. Brooklyn Investment Group lifted its stake in Teleflex by 258.6% during the first quarter. Brooklyn Investment Group now owns 208 shares of the medical technology company's stock worth $29,000 after purchasing an additional 150 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its stake in Teleflex by 57.9% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company's stock worth $26,000 after purchasing an additional 77 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. lifted its stake in Teleflex by 242.9% during the second quarter. Thurston Springer Miller Herd & Titak Inc. now owns 216 shares of the medical technology company's stock worth $26,000 after purchasing an additional 153 shares during the last quarter. Institutional investors own 95.62% of the company's stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.